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Abstract 
Background: National and regional authorities in Scotland have introduced multiple measures to 
appreciably enhance prescribing efficiency for the proton pump inhibitors (PPIs), statins and renin-
angiotensin inhibitor drugs. Generic oral risperidone recently became available in Scotland; however, 
schizophrenia is a complex disease with advice from respected authorities suggesting treatment 
should be individualised. Aims: Assess (i) changes in atypical antipsychotic (AAP) utilisation and 
expenditure following the availability of oral generic risperidone in Scotland, (ii) determine (a) current 
INN prescribing rates for risperidone following generic availability and (b) decrease in expenditure/ 
DDD for generic risperidone, (iii) suggest additional measures that could possibly be introduced in 
Scotland to further enhance prescribing of generic AAPs and (iv) provide guidance to NHS Scotland 
as well as other European authorities on the implications. Methods: Retrospective observational 
study and an interrupted time series design. Results: No appreciable change in the utilisation 
patterns of risperidone pre and post generic availability. Appreciable INN prescribing averaging 93% 
to 98% of total oral risperidone. Generic risperidone 84% below pre-patent loss prices by study end, 
reducing expenditure for risperidone in 2010 by GB£3.19mn compared with pre-patent loss situation. 
However, atypical expenditure increased overall by 42%. Discussion: As expected, no change in 
utilisation patterns for risperidone although potential to influence prescribing patterns. Continued high 
INN prescribing suggests no problems with generic risperidone in practice. Costs will start to 
decrease as more atypicals lose their patents (olanzapine and quetiapine). Possibility to accelerate 
this through educational activities. Conclusion: Potential to realise some savings with AAPs. 
However, has been limited by complexity of disease area. Any measures introduced must aim at 
increasing the prescribing of generic AAPs first line in suitable patients. 
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'What's known?'  
x Multiple and intensive demand side measures are needed to successfully influence physician 
prescribing and appreciably enhance prescribing efficiency 
x Schizophrenia is a complex disease area where limited differences in effectiveness between 
atypical antipsychotics (AAPs) apart from clozapine; however, differences in side-effects and 
response rates in individual patients. Consequently, greater tailoring of therapy than seen in other 
disease areas   
x Opportunity to release resources with generic AAPs. Some concerns though with the 
effectiveness of generic AAPs versus originators 
 
'What's new?' 
x Greater need to tailor AAPs potentially limits the opportunity to release appreciable resources 
from generic AAPs if most still patent protected 
x May be opportunities to instigate measures counteracting potential pressures from commercial 
organisations to enhance generic AAPs first line if no patient issues as AAP costs a high priority 
with now low costs of PPIs, statins and renin-angiotensin inhibitor drugs with generics 
x High INN prescribing of risperidone once available as a generic suggests no real problems in 
practice  
 
Background 
 
Scrutiny on pharmaceutical expenditure has intensified among health authorities and health insurance 
companies across Europe in recent years, with its growth outstripping other components of 
ambulatory care expenditure [1-8]. As a result, pharmaceutical expenditure is now typically the largest 
or equalling the largest cost component in ambulatory care [1-4,6-8]. This growth will continue unless 
addressed, driven by well known factors including changing demographics, rising patient expectations 
and the continued launch of new expensive drugs [1-3,5-9].  
 
These concerns have resulted in multiple reforms among European countries to improve the quality 
and efficiency of prescribing as resource pressures grow. Efficiency defined as utilisation increasing 
at a faster rate than expenditure in drug classes where all drugs are seen as similar in all or nearly all 
patients such as the proton pump inhibitors (PPIs), statins and renin-angiotensin inhibitor drugs [1-
8,10-16]. Multiple reforms for existing drugs include measures to obtain low prices for generics as well 
as enhance their utilisation versus originators and patented products in a class [1-8,10-18]. The 
objective being to conserve valuable resources as well as fund quality improvement programmes and 
new premium priced drugs [5-8,13,14,16]. 
 
The UK, including Scotland, is no exception. Supply-side measures and initiatives for generics include 
WKHLQWURGXFWLRQRIWKHµ0¶DQGµ:¶VFKHPHWRIXUWKHUORZHUthe price of generics, which resulted in the 
prices of high volume generics being as low as 2% to 3% of pre-patent loss originator prices 
[6,7,10,12,13,18,20,21]. Examples of demand-side measures generally as well as for the PPIs in 
Scotland include physicians trained in medical school to prescribe by International Non-proprietary 
name (INN), national guidance and guidelines (SIGN) as well as regional formularies; monitoring of 
prescribing, µ%HWWHU&DUH%HWWHU9DOXH¶LQGLFDWRUVWRHQKDQFHWKHSUHVFULELQJRIORZFRVWdrugs versus 
patented drugs in a class or related class; practice based financial incentives  as well as payment by 
results schemes [5-8,13,16,19-21]. These measures appreciably enhanced prescribing efficiency for 
high volume classes such as the PPs, e.g. reimbursed expenditure for PPIs in 2010 was 55% below 
2001 levels despite a 3 fold increase in utilisation during this period (defined daily doses [DDD] basis 
± 100.2 DDD/ TID in 2010 ± Thousand inhabitants per year), helped by increasing use of generic 
versus patented PPIs and expenditure/DDD for generic omeprazole in 2010 91% below 2001 
originator prices [16]. 
 
The utilisation of atypical antipsychotics has increased in recent years for the management of 
schizophrenia and bipolar disorders across Europe and the US [22-25]. This includes the UK where 
prescriptions for atypical antipsychotics in England rose from approximately 20% of all antipsychotic 
items in January to March 2000 to 67% in January to March 2007 [26]. The increase in prescribing of 
atypical antipsychotics appears to have been driven by meta-analyses and other studies suggesting 
greater efficacy and functional recovery as well as lower side-effects than typical antipsychotic drugs 
[23,27-29]. Alongside this, considerable increases in off-label use in recent years [30-34]. These 
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clinical improvements resulted in reports of improved compliance and persistence for atypical 
antipsychotics, although others have not seen this in practice [35-37]. As a result, in June 2002, the 
National Institute for Health and Clinical Excellence (NICE) in the UK recommended the use of 
atypical (newer) oral antipsychotic drugs in people with newly diagnosed with schizophrenia and 
those currently taking typical (older) antipsychotic drugs where their symptoms are being controlled 
but there are side effects with these drugs [38]. NICE recently updated its guidance for patients with 
newly diagnosed schizophrenia offered oral antipsychotic medication [39], stating that healthcare 
professionals VKRXOGµSURYLGH information and discuss the benefits and side-effect profile of each drug 
with the service user. The choice of drug should be made by the service user and healthcare 
professional together, considering: 
x the relative potential of individual antipsychotic drugs to cause extrapyramidal side effects 
(including akathisia), metabolic side effects (including weight gain) and other side effects 
(including unpleasant subjective experiences) 
x WKHYLHZVRIWKHFDUHUZKHUHWKHVHUYLFHXVHUDJUHHV¶ 
 
NICE also suggested that for people with schizophrenia whose illness has not responded adequately 
to pharmacological or psychological treatment healthcare professionals should [39]: 
x review the diagnosis 
x establish that there has been adherence to antipsychotic medication, prescribed at an adequate 
dose and for the correct duration 
x review engagement with and use of psychological treatments and ensure that these have been 
offered according to this guideline. If family intervention has been undertaken suggest cognitive 
behavioural therapy (CBT); if CBT has been undertaken suggest family intervention for people in 
close contact with their families 
x consider other causes of non-response, such as comorbid substance misuse (including alcohol), 
the concurrent use of other prescribed medication or physical illness 
In addition, physicians should offer clozapine to people with schizophrenia whose illness has not 
responded adequately to treatment despite the sequential use of adequate doses of at least two 
different antipsychotic drugs. At least one of the drugs should be a non-clozapine second-generation 
antipsychotic [39]. 
 
However, there have been concerns about the quality of the evidence and the extent of the 
differences in practice in the effectiveness of typical versus atypical antipsychotics [38]. This 
especially with growing criticism that high-potency haloperidol (typical antipsychotic) was used as a 
comparator in the studies with second generation (atypical antipsychotics) thereby biasing the results, 
and only a limited number of studies used medium-potency first generation (typical) antipsychotics as 
the comparator [35,36]. Alongside this, greater levels of side-effects such as weight gain, 
hyperlipidaemia and Type 2 diabetes with atypical antipsychotics [22,39-41]. In addition, the risk of 
QT prolongation and subsequent arrhythmia-related events, i.e. Torsade de Pointes (TdP) and 
Sudden Cardiac Death, is being increasingly seen as one of the most important safety aspect to 
consider when patients are prescribed atypical antipsychotic drugs [44,45]. In the past, atypical 
antipsychotic drugs have been perceived as generally having a favourable cardiac safety profile 
compared with typical antipsychotic drugs. However, these beliefs have been undermined by a recent 
cohort study finding a dose-dependent increased risk of sudden cardiac deaths among current users 
[46], further corroborated by different case series [47] as well as pharmacovigilance analyses [48,49], 
showing similar reporting ratios between typical and atypical antipsychotic drugs in clinical practice. 
Tiihonen and colleagues have also recently shown that the highest risk of mortality in patients with 
schizophrenia prescribed atypical antipsychotic drugs compared to pherphenazine was seen with 
quetiapine with the lowest with clozapine [50]. Haloperidol and risperidone slightly lower adjusted 
hazard ratios than quetiapine [50]. In June 2008, the FDA also notified healthcare professionals that 
both typical (conventional) and atypical antipsychotics are associated with an increased risk of 
mortality in elderly patients treated for dementia-related psychosis (unlabeled indication) [51]. 
 
These debates have continued with the publication of the various findings from the Clinical 
Antipsychotic Trials of Intervention Effectiveness (CATIE) study in the US showing limited differences 
between the various antipsychotics, although this is not without criticism [22,52-54].  The various 
VWXGLHVVXJJHVWWKDWµWKHnumerous antipsychotic drugs, however they might be classified, are more 
similar to than different from each other. To the extent that antipsychotics differ, it is more in their side 
effects than therapeutic effects. Nevertheless, there is variation in the effectiveness of antipsychotic 
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drugs, which for individual patients can be substantial, and what works for one person may not work 
for another. Consequently, treatments for schizophrenia must be individualized¶ [53]. Recent reviews 
by the Cochrane Collaboration and others would suggest that olanzapine may be a somewhat more 
efficacious than some other second generation antipsychotic drugs, with mixed results with 
risperidone. However, these conclusions are tentative due to the large dropout rates in most studies 
[55-58]. In addition, re-analysis of the CATIE study suggests that unless the clinical situation requires 
a medication change, it may be best for patients to optimise current medication regimens rather than 
switching medications with no apparent gains with switching therapies [59,60]. 
 
Other authors though believe the modest gains with atypical antipsychotic drugs that have reported 
do not adequately reflect the improvements in quality of life perceived by patients, clinicians or carers 
[61]. This may be important especially with family support appearing to make a difference with 
outcomes in practice [62]. 
 
In any event, utilisation of atypical anti-psychotic drugs continues to increase, which is likely to remain 
[22-26]. Consequently, the availability of generic atypical antipsychotics should be welcomed by 
health authorities in the UK where initiatives to lower prices for generics, coupled with high INN 
prescribing rates, has led to low prices for generics [5,6, 14-16]. The first atypical antipsychotic drug 
to become available as a generic in the UK was clozapine, with published studies, including those 
from the UK, showing no difference in outcomes between the originator and generics in practice once 
initial the problems in the US had been resolved [22,63-66]. More recently, generic olanzapine and 
generic risperidone have become available across Europe with again no apparent patient issues in 
practice [18,22,67,68], although some are more cautious [68,69].  
 
It is recognised though that schizophrenia and other conditions such as bipolar disorders are more 
complex to treat than stomach related acid disorders, hypercholesterolaemia or hypertension. In 
addition as documented, atypical antipsychotic drugs should not be considered as one class 
containing similar products unlike the PPIs, statins or renin-angiotensin drugs [3,5-8,10,11,14-17,70] 
As a result, greater necessity for tailoring treatments depending on the patient and their 
characteristics having considered the safety profile of the drug, e.g. olanzapine should not be 
considered in young ladies with weight problems or risperidone in patients with sexual problems. In 
addition, switching should only be considered if patients are failing on their current treatment, or 
having undue side-effects from their current treatment, having considered that it may be best for 
patients to optimise current medication regimens before switching [59,60]. Having said this, there may 
be a number of patients who could be started on a number of different antipsychotic drugs. In this 
situation, it would be sensible for physicians to start patients on a generic atypical antipsychotic, 
which is the advice given by NICE and Lothian Health Board [39,71,72]. Alongside this enhancing the 
utilisation of generic oral tablets versus patented premium priced orodispersible tablets [72]. 
 
Consequently, the availability of oral generic risperidone versus patented olanzapine, quetiapine, 
aripiprazole and zotepine, should in theory lead to increased prescribing of risperidone first line 
among patients where there are a number of treatment options. This building on general initiatives in 
Scotland to enhance the prescribing of generics, e.g. a Hawthorne effect [73-76], especially as 
olanzapine and quetiapine were among the ten highest expenditure drugs in Scotland in 2010 [77]. 
 
Aims 
 
The principal aim is to assess the changes in atypical antipsychotic drug utilisation and expenditure 
patterns in Scotland following the availability of oral generic risperidone in April 2008. In addition (a) 
determine current INN prescribing rates for risperidone following generic availability, (b) the decrease 
in expenditure/ DDD for generic risperidone versus pre-patent loss prices over time and compare 
these with the situation seen with generic PPIs and statins, (c) suggest additional measures that could 
possibly be introduced in Scotland to further enhance the prescribing of generic atypical 
antipsychotics given the complexities of the situation, (d) provide guidance to NHS Scotland as well 
as other European health authorities and health insurance companies on the implications of the 
findings. 
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Methodology 
 
Two methodologies were utilised. The first involved a retrospective observational study of the 
utilisation and reimbursed expenditure in the administrative database of NHS National Services 
Scotland Corporate Warehouse of all patients in Scotland dispensed at least one atypical 
antipsychotics (Olanzapine ± N05AH03, quetiapine ± N05AH04, amisulpride ± N05AL05, risperidone 
± N05AX08, zotepine ± N05AX11, aripiprazole ± N05AX12 and paliperidone ± N05AX13) between 
2005 and 2010, i.e. 2 full years before the availability of oral generic risperidone in April 2008 and two 
full years after [78,79]. Clozapine was not included in this analysis as this is reserved for resistant 
patients due to its side-effect profile [22,23, 28,63,65,80-82]. Asenepine (N05AH05) and clotiapine 
(N05AH06) were never reimbursed in Scotland; consequently, also not included in the analysis. 
 
The second study was an interrupted time series design to analyse the changes in monthly 
reimbursed prescriptions in the administrative database of NHS National Services Scotland Corporate 
Warehouse of all patients in Scotland dispensed at least one atypical antipsychotic (N05AH03 to 05, 
N05AL05, N05AX08,11 to 13) between April 2006, i.e. 2 years before oral generic risperidone was 
reimbursed, to September 2011 some 41 months after oral generic risperidone was reimbursed. 
 
The two methodologies were chosen to provide different data sets. The monthly data will help 
demonstrate more visibly any ongoing changes in atypical antipsychotic utilisation patterns before and 
after the availability of oral generic risperidone. The yearly data will help assess overall changes in 
expenditure patterns for comparison with other drug classes. All comparator data with other classes 
has been taken from previously published studies of Scotland by the co-authors (MB, IB, SC, BBG). 
 
8WLOLVDWLRQZDVFROODWHGLQWHUPVRI'''VZLWK'''VGHILQHGDVµthe average maintenance dose of a 
drug when used in its major indication in adults¶DVWKLVPHDVXUHLVUHFRJQLVHGDVWKHLQWHUQDWLRQDO
standard to assess utilisation patterns within and between countries [78,79]. 2011 DDDs were used in 
line with international guidance [5-8,79,83]. 
 
Serial autocorrelations of risperidone DDDs were assessed in the interrupted time series design using 
an ARIMA model and a Box-Jenkins-Tiao strategy [84]. DDDs were plotted over time in months. The 
graphs were visually inspected to assess the trends or the nonstationarity of the data.  Alongside this, 
a segmented regression analysis of the interrupted time series was used to assess the effect of the 
availability of generic risperidone in April 2008 on its subsequent utilization versus other atypical 
antipsychotics. Common segmented regression models were used to fit a least-squares regression 
line to each segment of the independent variable (time t), assuming a linear relationship between time 
and the outcome within each segment. The effect of the intervention (generic risperidone) was 
assessed with using the model: Yt = ȕ0 + ȕ1 (timet  «) + ȕ2 (intervention 1t) + ȕ3 (time after 
intervention 1 t) + ȕ4 ȕ2 (intervention 2 t) + ȕ5 (time after intervention 2 t)+ et, where Yt was risperidone 
DDDs per month t, time is a continuous variable indicating time (in months) at time t from the start 
until the end of the observation period, intervention is an indicator variable for time t occurring before 
(t = 0 month) or after (t = 1 month) reimbursement of generic risperidone, and et is the error term at 
time t [85]. The time after reimbursement (months) is a continuous variable that counts the number of 
months after the intervention at time t, coded time 0 before the intervention (April 2008). The Durbin-
Watson statistic was calculated to test for a serial autocorrelation of the error terms in the regression 
models [86]. The statistical package IBM SPSS Statistics version 19.0 was used for all analyses. A P 
value of <0.05 was considered significant [87]. 
 
We are confident we can undertake this type of analysis as there were no major demand-side 
measures instigated across Scotland in direct response to the availability of generic risperidone apart 
from the formulary guidance of Lothian Health Board in recent years [72]. 
 
Reimbursed expenditure was used as these are the costs incurred by NHS Scotland, which is the 
perspective of the paper. This is in line with previous studies, and facilitates comparisons with other 
countries [5-8,12,14,16]. There has been no allowance for inflation as typically health authorities 
throughout Europe seek to reduce drug prices if expenditure for pharmaceuticals is rising more rapidly 
than agreed amounts [1-3,5,7,8,88]. In addition, introduce measures to lower the price for generics 
over time [1-6,8,14,17,22]. Scotland is no exception [6-8,16].  
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Results 
 
There was a 53% increase in the utilisation of atypical antipsychotic drugs during the course of the 
study, rising from 3.4DDD/ TID in 2005 to 5.1 in 2010, driven by increasing utilisation of olanzapine, 
quetiapine and aripiprazole (Figure 1).  
 
Figure 1 ± DDD/ TID for atypical antipsychotic drugs in Scotland 2005 to 2010 
 
Generic oral risperidone
 
As a result, the utilisation of risperidone as a % of total DDDs for the atypical anti-psychotics 
decreased steadily from 21% in 2005 to 16% in 2010 (Figure 2). However, during this period the 
utilisation of long-acting risperidone injections increased from 3.8% of total risperidone (DDD basis) in 
2005 to 6.5% in 2010. 
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Figure 2 - % utilisation of different atypical anti-psychotics (DDD basis) 2005 to 2010 
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There was high utilisation of oral generic risperidone, with INN prescribing averaging 93% to 98% of 
total oral risperidone on a DDD basis following the availability of generics. 
 
The monthly DDD utilisation data also showed no change in overall utilisation patterns for risperidone 
versus other atypical antipsychotics before and after the availability of generic risperidone (Figures 3 
and 4, Table 1), with any increase in the utilisation of risperidone mirroring the increase in the 
utilisation of atypical antipsychotic drugs generally. However, the rate of increase was lower as 
demonstrated by decreasing utilisation of risperidone versus all atypical antipsychotic drugs since the 
availability of generic risperidone. 
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Figure 3 ± Monthly DDDs for atypical in Scotland April 2006 to September 2011 
 
Generic risperidone available
 
 
 
Table 1 - Parameter estimates, standard errors and P-values from the segmented regression model 
predicting the extent of risperidone DDDs before and after generic risperidone (Coefficient variable is 
risperidone DDDs) 
 
 
Coefficientsa 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence Interval for B 
B Std. Error Beta Lower Bound Upper Bound 
1 (Constant) 106768.517 2051.570 
 
52.042 .000 102667.486 110869.547 
Time 156.516 143.580 .415 1.090 .280 -130.497 443.528 
Reimbursement 900.263 2460.617 .060 .366 .716 -4018.440 5818.967 
Time after reimbursement 151.781 156.388 .299 .971 .336 -160.835 464.397 
a. Dependent Variable: Risperidone DDDs 
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Figure 4 ± Change in utilization patterns for risperidone (DDDs reimbursed) over time before and after 
generic risperidone  
 
 
  
 
 
Reimbursed expenditure for atypical antipsychotics grew by 42% during the study period, increasing 
from £4662/ 1000 inhabitants/ year in 2005 to £6512/ 1000 inhabitants/ year in 2010. This increase 
was lower than the increase in utilisation, facilitated by reimbursed expenditure/ DDD for generic oral 
risperidone at GB£0.47p in 2010, 84% below pre-patent loss prices. This reduction in expenditure/ 
DDD for generic oral risperidone reduced expenditure for risperidone in 2010 by GB£3.19mn 
compared with the pre-patent loss situation.   
 
Discussion  
 
As expected, there was no appreciable change in the utilisation pattern for risperidone versus other 
atypical antipsychotics following the availability of generic risperidone (Figures 3 and 4, Table 1). This 
may well reflect the advice from NICE and the conclusions of the various Cochrane reviews and 
CATIE studies that treatments should be tailored to the individual [39,41,42,53-56] as schizophrenia 
and bipolar disease are far more complex to treat than those treated with the PPIs, statins, ACEIs or 
ARBs. Consequently, no apparent Hawthorne effect [73-76]. However, this will need further research 
before any definite conclusions can be drawn especially with the growing utilisation of the patented 
atypical antipsychotic drugs (quetiapine and aripiprazole) during the study period, reducing utilisation 
of risperidone as a % of atypical antipsychotic drugs (Figures 1 and 2), and substantial fines for 
Johnson and Johnson and AstraZeneca in the US for inappropriate marketing activities [31-34]. The 
off-label utilisation of atypical antipsychotics requires close monitoring by the regulatory and health 
authorities in view of the limited clinical benefit of atypical antipsychotic drugs in some patients 
coupled with potentially life-threatening events [30,89].  
 
As a result, there may be opportunities for Health Board personnel to work with psychiatrists to see 
whether there could be more patients started on generic atypical antipsychotic drugs where choices 
භ Before generic risperidone 
භĨƚĞƌŐĞŶĞƌŝĐƌŝƐƉĞƌŝĚŽŶĞ 
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are available having considered all the potential side-effect issues. This may now become easier with 
oral olanzapine losing its patent at the end of 2011 and quetiapine in March 2012 [I. Bishop Personal 
communication]. Both situations should appreciably reduce reimbursed expenditure for the atypical 
antipsychotics in Scotland as they are the most prescribed ones (Figures 1 and 3), and we have 
already seen a considerable reduction in expenditure/ DDD for generic risperidone. This will be 
welcomed as expenditure/ 1000 inhabitants/ year for atypical antipsychotics in Scotland in 2010 was 
already higher than expenditure for the PPIs despite appreciably lower utilisation rates at 5.1 DDD/ 
TID versus 100.2 for the PPIs [16]. In addition, reimbursed expenditure/ 1000 inhabitants/ year for the 
statins in 2010 was only 75% higher than that for the atypical antipsychotic drugs in 2010 despite 
utilisation rates of over 140DDD/ TID for the statins. Any activities though must be carefully 
considered in view of more atypical antipsychotic drugs becoming available as generics and any 
activities undertaken would divert attention from already agreed quality and efficiency initiatives in 
Scotland in 2012 [90]. This especially if more sophisticated analyses are undertaken with patient 
databases rather than consolidated drug utilisation databases such as exploring current and future 
atypical antipsychotic drug sequencing. This is a possibility in Scotland with its sophisticated 
databases linking ambulatory and secondary care. We recognised this is a limitation of the current 
study methodology, which we will be looking to address in further research. However, in the meantime 
we believe our findings are of interest to other countries. 
 
One area though for further analysis is the increasing utilisation of long-acting risperidone injections 
(RLAI) as a percentage of total risperidone. This is in view of its considerably higher price on an 
expenditure/ DDD versus generic oral risperidone, and ongoing concerns regarding its increased 
efficiency in practice given that most of the published studies with RLAI are open label and subject to 
sponsor bias coupled with a number of independent randomised and observational studies showing 
no benefit versus oral treatments [91-98]. This will now be looked at further within NHS Scotland. 
 
We believe an important finding was the high INN prescribing of oral risperidone during the study 
period with community pharmacists in the UK not allowed to substitute an originator for a generic if 
the physician prescribes the originator. This suggests no perceived problems with oral generic 
risperidone in Scotland during the considerable time period when it has been available, mirroring 
other countries [18,22]. This will help address some of the concerns voiced about the quality and 
effectiveness of generic atypical antipsychotics [18, 22, 64,65]. High INN prescribing also reduces any 
patient confusion that can exist in countries with branded generics [4,14,16], which is likely to be 
beneficial in this patient population. Both these points are important for health authorities and health 
insurance agencies seeking to increase their utilisation of generic atypical antipsychotics to conserve 
valuable resources without compromising care, given current high expenditures on atypical 
antipsychotic drugs. 
 
Low prices for generic risperidone versus pre-patent loss prices also mirrors the situation seen with 
generic omeprazole and generic simvastatin in the UK [5,8,14,16]. The savings from the availability of 
oral generic risperidone will be enhanced with envisaged further reductions in expenditure/ DDD of 
risperidone over time, mirroring the situation for other generics in the UK [14,16]. 
 
In conclusion, it is difficult to transfer the multiple demand-side measures used to enhance prescribing 
efficiency for the PPIs, statins and renin-angiotensin drugs to complex disease areas such as 
schizophrenia, especially with the atypical antipsychotic drugs not considered as interchangeable 
coupled with physicians tending to individualise treatment depending on the patient. However, there 
may be opportunities to enhance the prescribing of generic atypical antipsychotics first line if multiple 
choices are available with educational and other demand-side measures to counteract commercial 
company activities. Such activities could also help reduce off-label use of atypical antipsychotic drugs 
where this is considered an issue. On a positive note, there appears to be no problems with generic 
risperidone in Scotland as seen by the continued high INN prescribing rates. This should be 
welcomed by authorities across Europe. 
 
 11 
 
Financial disclosure and acknowledgements 
 
MB and IB are employed by NHS Scotland. The authors have no other conflicts of interest to declare.  
 
This work was in part supported by grants from the Karolinska Institutet, Sweden. 
 
No writing assistance was provided for this paper. 
 
References 
 
1. Godman B, Bucsics A, Burkhardt T, Haycox A, Seyfried H, Wieninger P. Insight into recent 
reforms and initiatives in Austria; implications for key stakeholders. Expert Rev 
Pharmacoeconomcis Outcomes Research 2008; 8:357-371  
2. Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, Reynier JP. Ongoing pharmaceutical 
reforms in France; implications for key stakeholder groups. Applied Health Economics and Health 
Policy 2010;8:7-24 
3. Coma A, Zara C, Godman B, Augusti A, Diogene E, Wettermark B, Haycox A. Policies to 
enhance the efficiency of prescribing in the Spanish Catalan Region: impact and future direction. 
Exp Review of Pharmacoeconomics and Outcomes Research 2009; 9: 569-81 
4. :HWWHUPDUN%*RGPDQ%$QGHUVVRQ.*XVWDIVVRQ//+D\FR[$%HUWHOH¶95HFHQWQDWLRQDO
and regional drug reforms in Sweden ± implications for pharmaceutical companies in Europe. 
Pharmacoeconomics 2008; 26: 537-50  
5. Godman B, Shrank W, Wettermark B, Andersen M, Bishop I et al. Use of generics ± a critical cost 
containment measure for all healthcare professionals in Europe?  Pharmaceuticals 2010; 3:2470-
94 doi 10.3390/ph/3082470 ISSN 1424-8247 
6. 9RQþLQD/6WUL]UHS7*RGPDQ%%HQQLH0%LVKRS,&DPSEHOO69ODKRYLF3DOFHYVNL9
Gustafsson LL. Influence of demand side measures to enhance renin-angiotensin prescribing 
efficiency in Europe; implications for the future. Expert Rev Pharmacoeconomics and Outcomes 
Res 2011; 11: 469-79 
7. Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T et al. Comparing policies to 
enhance prescribing efficiency in Europe through increasing generic utilisation: changes seen and 
global implications. Expert Rev. Pharmacoeconomics Outcomes Res 2010; 10: 707±22 
8. Godman B, Shrank W, Andersen M, Berg C,  Bishop I, Burkhardt T, Garuoliene K et al. Policies to 
enhance prescribing efficiency in Europe: findings and future implications. Frontiers Pharmacol. 
2011; 1 (141): 1-16 doi: 10.3389/fphar.2010.00141 
9. Garattini S, Bertele V, Godman B, Haycox A, Wettermark B, Gustafsson LL. Enhancing the 
rational use of new medicines across European healthcare systems ± A Position Paper. Eur Jn 
Clinical Pharmacology 2008; 64:1137±8 
10. Godman B, Haycox A, Schwabe U et al. Having your cake and eating it: Office of Fair Trading 
proposal for funding new drugs to benefit patients and innovative companies. 
Pharmacoeconomics 2008; 26:91-98  
11. Norman C, Zarrinkoub R, Hasselström J, Godman B, Granath F, and Wettermark B. Potential 
savings without compromising the quality of care. Int J Clin Pract 2009: 63:1320±26 
12. Godman B, Sakshaug S, Berg C, Wettermark B, Haycox A. Combination of prescribing 
restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev. 
Pharmacoeconomics Outcomes Res. 2011; 11: 121±9 
13. Godman B, Malmstrom RE, Bennie M, Sakshaug S, Burkhardt et al. Prescribing restrictions - a 
necessary strategy among some European countries to enhance future prescribing efficiency? 
Reviews in Health Care 2012; 3: 5-16 
14. McGinn D, Godman B, Lonsdale J, Way R, Wettermark B, Haycox A. Initiatives to enhance the 
quality and efficiency of statin and PPI prescribing in the UK; impact and implications. Expert Rev 
Pharmacoeconomics and Outcomes Res 2010; 10: 73-85 
15. Gustafsson  LL, Wettermark B, Godman B, Andersén-.DUOVVRQ(%HUJPDQ8HWDO7KH³:LVH
/LVW´- A comprehensive concept to select, communicate and achieve adherence to 
recommendations of essential drugs in ambulatory care in Stockholm. Basic & Clinical 
Pharmacology & Toxicology 2011; 108:224-233 
16. Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the 
prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Review 
Pharmacoeconomics and Outcomes Research 2012; 12: 125-130 
 12 
 
17. Garuoliene K, Godman B, *XOELQRYLþ J, Wettermark B, Haycox A. European countries with small 
populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev. 
Pharmacoeconomics Outcomes Res 2011; 11: 343-9 
18. Araszkiewicz AA, Szabert K, Godman B, Wladysiuk M, Barbui C, Haycox A. Generic olanzapine: 
health authority opportunity or nightmare? Expert Rev Pharmacoeconomics Outcomes Res 2008; 
8:549-55 
19. SIGN. Dyspepsia ± a national clinical guideline. March 2003. Available via URL: 
http://www.sign.ac.uk/pdf/sign68.pdf [Accessed 10 November 2011] 
20. SIGN. Secondary prevention of CHD following Myocardial Infarction. 2000. Available via URL: 
http://www.nhsggc.org.uk/content/mediaassets/pdf/HSD/sign41.pdf [Accessed 13 Nov 2011 
21. SIGN. Management of Diabetes. 2001 Available via URL: http://www.sign.ac.uk/pdf/qrg55.pdf 
[Accessed 13 Nov 2011] 
22. Wladysiuk M, Araszkiewicz A, Godman B, Szabert K et al. Patient co-payments do influence 
atypical antipsychotic choice in Poland; implications once generic atypcials are available. Appl 
Health Econ Health Policy. 2011; 9: 101-10 
23. Knapp M, Kanavos P, King D, et al. Economic issues in access to medications: schizophrenia 
treatment in England. Int J Law Psychiatry 2005; 28: 514-31 
24. Mirandola M, Andretta M, Corbari L, et al. Prevalence, incidence and persistence of antipsychotic 
drug prescribing in the Italian general population: retrospective database analysis, 1999±2002. 
Pharmacoepidemiol Drug Saf 2006; 15: 412-20 
25. Crystal S, Olfson M, Huang C, et al. Broadened use of atypical antipsychotics: safety, 
effectiveness, and policy challenges. Health Aff 2009; 28 (5): 770-81 
26. NICE implementation uptake report: atypical antipsychotic drugs for the treatment of 
schizophrenia. NICE Technology appraisals 43. Available via URL: 
http://www.nice.org.uk/media/410/E9/ImplUptakeReportAtypicalAntipsychotics.pdf 
27. Mond J, Morice R, Owen C, et al. Use of antipsychotic medications in Australia between July 
1995 and December 2001. Aust N Z J Psychiatry 2003; 37: 55-61 
28. Leucht S, Corvers C, Arbter D, et al. Second-generation versus first-generation antipsychotic 
drugs for schizophrenia: a meta-analysis. Lancet 2009; 373 (9657): 31-41 
29. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. Relapse prevention in 
schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus 
first-generation antipsychotics. Mol Psychiatry. 2011 Nov 29. doi: 10.1038/mp.2011.143. [Epub 
ahead of print] 
30. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of 
antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 
2011;20:177-84 
31. Leslie D, Rosenheck R. Off-Label Use of Antipsychotic Medications in Medicaid. Am J Manag 
Care. 2012;18(3):e109-e117 
32. Fisk M, Feeley J, Voreacos D. J&J Said to Agree to $2.2 Billion Drug Marketing Accord. Available 
via URL: (http://www.bloomberg.com/news/2012-06-11/j-j-said-to-pay-2-2-billion-to-end-risperdal-
sales-probe.html [Accessed 18 September 2012] 
33. Department of Justice settlement agreement. Available via URL: 
http://www.justice.gov/usao/pae/Pharma-Device/astrazeneca_settlementagreement.pdf 
[Accessed 18 September 2012] 
34. Jack A. AstraZeneca faces $520m Seroquel fine. Available via URL: 
http://www.ft.com/cms/s/0/319e31d4-5251-11df-8b09-00144feab49a.html#axzz26q1gMSgc 
[Accessed 18 September 2012] 
35. Ren XS, Qian S, Lee AF, et al. Treatment persistence: a comparison among patients with 
schizophrenia who were initiated on atypical antipsychotic agents. J Clin Pharm Ther 2006; 31: 
57-65 
36. Taylor DM, Wright T, Libretto S. Risperidone compared with olanzapine in a naturalistic clinical 
study: a cost analysis. J Clin Psychiatry 2003; 64: 589-97 
37. Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with 
schizophrenia: medication and patient factors. Schizophr Bull 2004; 30: 255-64 
38. Walley T. Neuropsychotherapeutics in the UK. What has been the impact of NICE on prescribing? 
CNS Drugs 2004; 18 (1): 1-12 
39. NICE. Schizophrenia - Core interventions in the treatment and management of schizophrenia in 
adults in primary and secondary care. NICE ClinicalGuideline 82.  Issued March 2009. Available 
via URL: http://www.nice.org.uk/nicemedia/live/11786/43610/43610.pdf 
 13 
 
40. Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency 
conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361 (9369): 
1581-9 
41. Tyrer P, Kendall T. The spurious advance of antipsychotic drug therapy. Lancet 2009; 373 (9657): 
4-5 
42. Gardner D, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 
2005; 172 (13): 1703-11 
43. Andretta M, Ciuna A, Corbari L, et al. Impact of regulatory changes on first- and second-
generation antipsychotic drug consumption and expenditure in Italy. Soc Psychiatry Psychiatr 
Epidemiol 2005; 40: 72-7 
44. Titier K, Girodet PO, Verdoux H, Molimard M et al. Atypical antipsychotics: from potassium 
channels to torsade de pointes and sudden death. Drug Safety 2005;28(1):35-51  
45. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics : differential risk and clinical 
implications. CNS Drugs 2007; 21(11):911-936 
46. Ray WA, Chung CP, Murray KT et al. Atypical antipsychotic drugs and the risk of sudden cardiac 
death. NEJM. 2009;360(3):225-35 
47. Vieweg WV, Wood MA, Fernandez A. Proarrhythmic risk with antipsychotic and antidepressant 
drugs: implications in the elderly. Drugs Aging. 2009;26(12):997-1012 
48. Poluzzi E, Raschi E, Moretti U, De Ponti F. Drug-induced torsades de pointes: data mining of the 
public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug 
Saf. 2009 Jun;18(6):512-8. 
49. Meyer-Massetti C, Vaerini S, Rätz Bravo AE et al. Comparative safety of antipsychotics in the 
WHO pharmacovigilance database: the haloperidol case. Int J Clin Pharm. 2011 Oct;33(5):806-14 
50. Tiihonen J, Lönnqvist J, Wahlbeck W et al.  11-year follow-up of mortality in patients with 
schizophrenia: a population-based cohort study (FIN11 study). Lancet 13 July 2009. 
DOI:10.1016/S0140-6736(09)60742-X 
51. US FDA. Information for Healthcare Professionals: Conventional Antipsychotics. Available via 
URL: 
http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/uc
m124830.htm [Accessed 20 September 2012] 
52. Lieberman JA, Stroup TS, McEvoy JP et al.  Effectiveness of antipsychotic drugs in patients with 
chronic schizophrenia. N Engl J Med 2005; 353:1209±1223 
53. Lieberman JA, Stroup T. Commentary - The NIM H-CAT IE Schizophrenia Study: What did we 
learn? Am J Psychiatry 2011; 168:770-5 
54. Berkowitz RL, Patel U, Ni Q, Parks JJ, Docherty JP. The impact of the Clinical Antipsychotic 
Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a 
large midwestern state. J Clin Psychiatry. 2012; 73(4):498-503. Epub 2011 Dec 13 
55. Komossa K, Rummel-Kluge C, Hunger H et al. Olanzapine versus other atypical antipsychotics for 
schizophrenia. Cochrane Database of Systematic Reviews 2010, Issue 3. Art. No.: CD006654. 
DOI: 10.1002/14651858.CD006654.pub2 
56. Komossa K, Rummel-Kluge C, Schwarz S et al. Risperidone versus other atypical antipsychotics 
for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 1. Art. No.: CD006626. 
DOI: 10.1002/14651858.CD006626.pub2 
57. Hargreaves WA, Gibson JP. Effectiveness and cost of risperidone and olanzapine for 
schizophrenia: a systematic review. CNS Drugs 2005; 19: 393-410 
58. Heres S, Davis J, Maino K, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, 
and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of 
second-generation antipsychotics. Am J Psychiatry 2006; 163: 185-94 
59. Essock SM, Covell NH, Davis SM, Stroup TS et al. Effectiveness of switching antipsychotic 
medications. Am J Psychiatry. 2006; 163(12): 2090-5 
60. Rosenheck RA, Davis S, Covell N et al. Does switching to a new antipsychotic improve 
outcomes? Data from the CATIE Trial. Schizophr Res. 2009; 107(1):22-9 
61. Magnus A, Carr V, Mihalopoulos C, et al. Assessing cost-effectiveness of drug interventions for 
schizophrenia. Aust N Z J Psychiatry 2005; 39: 44-54 
62. Glick ID, Stekoll AH, Hays S. The role of the family and improvement in treatment maintenance, 
adherence, and outcome for schizophrenia. J Clin Psychopharmacol. 2011;31:82-5. 
63.  Healy DJ, Taylor S, Goldman M, Barry K, Blow F, Milner KK. Clinical equivalence of generic 
clozapine. Community Ment Health J 2005; 41(4): 393-8  
 14 
 
64. Alessi-Severini S, Honcharik PL, Simpson KD Eleff MK, Collins DM. Evaluation of an 
interchangeability switch in patients treated with clozapine: A retrospective review. J Clin 
Psychiatry 2006; 67(7): 1047-54  
65. Paton C. Generic clozapine: outcomes after switching. Br J Psychiatry  2006; 89: 184-5 
66. Bazire S, Burton V. Generic clozapine in schizophrenia: what is all the fuss about? 
Pharmaceutical Jn 2004; 173: 720-1 
67. Khorana N, Maphanta S, Lohitnavy O, Srichaiya A, Sayasathid J. Comparative pharmacokinetics 
and bioequivalence of two tablet formulations of 2 mg risperidone in healthy Thai male volunteers. 
Int J Clin Pharmacol Ther. 2011; 49:409-14 
68. Correl C, Carbon M. Brand vs. generic psychotropic medication. Is one better than the other? 
Available via URL: 
https://www.nwpmd.com/LinkClick.aspx?fileticket=vr6K7kfBUfc%3D&tabid=342 
69. Desmarais JE, Beauclair L, Margolese HC. Switching from brand-name to generic psychotropic 
medications: a literature review. CNS Neurosci Ther. 2011;17:750-60. doi: 10.1111/j.1755-
5949.2010.00210.x. Epub 2010 Nov 30. 
70. Moon J, Flett A, Godman B, Grosso A, Wierzbicki A. Getting better value from the NHS drug 
budget. BMJ 2011; 342: 30-32 
71. WHO Model List of Essential Medicines and developed countries: a comparison with the Lothian 
Joint Formulary. WHO Drug Information 2006; 20:73-7 
72. Lothian Formulary. Available via URL: 
http://www.ljf.scot.nhs.uk/LothianJointFormularies/Adult/4.0/4.2/4.2.1/(a)/Pages/default.aspx  
73. Holden J. Hawthorne effects and research into clinical practice. Jn Evaluation Clin Practice 2001; 
7; 65-70 
74. Konstantinou G3UDJPDWLFWULDOVKRZWRDGMXVWIRUWKHµ+DZWKRUQHHIIHFW¶" Thorax  2011;-:1. 
doi:10.1136/thoraxjnl-2011-200657 
75. Trietsch J, van der Weijden T, Verstappen W et al. A cluster randomized controlled trial aimed at 
implementation of local quality improvement collaboratives to improve prescribing and test 
ordering performance of general practitioners: Study Protocol. Implementation Science 4:6 
doi:10.1186/1748-5908-4-6 (2009) 
76. Verstappen WHJM, Weijden T van der, ter Riet G, Grimshaw J, Winkens R, Grol R. Block design 
allowed for control of the Hawthorne effect in a randomized controlled trial of test ordering. 
Journal of Clinical Epidemiology 2004, 57:1119-1123 
77. Godman B. Actions to improve the efficient and safe use of drugs: what can we learn from 
international experiences? 8th Conference of Discussion of Pharmaceutical Spending on Health 
Managers and Their Impact on Sustainability of the System and  6th Conference of Debate on the 
Effectiveness and Safety in the Use of Drugs - 
http://www10.gencat.cat/catsalut/archivos/jornades/farmacia/8a/Conferencia_inaugural_Godman.
pdf [Accessed 19 September 2012] 
78. World Health Organisation (WHO) Guidelines for ATC classification and DDD assignment 2009. 
Oslo: WHO Collaborating Centre for Drug Statistics Methodology. www.whocc.no [Accessed 5 
March 2012] 
79. World Health Organization (WHO). Introduction to Drug Utilisation Research. WHO International 
Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics 
Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical 
Pharmacological Services. ISBN 92 4 156234 X (NLM classification: WB 330) Available via URL: 
http://www.who.int/medicines/areas/quality_safety/safety_efficacy/Drug%20utilization%20researc
h.pdf [Accessed 3 March 2012] 
80. Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Leucht S. 
Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 
2010 Nov 10;(11):CD006633. 
81. Leucht S, Heres S, Kissling W, Davis JM. Evidence-based pharmacotherapy of schizophrenia. Int 
J Neuropsychopharmacol. 2011 Mar;14(2):269-84. Epub 2011 Jan 6. 
82. Raja M. Clozapine safety, 35 years later. Curr Drug Saf. 2011 Jul;6(3):164-84 
83. Vlahovic-Palcevski V, Gantumur M, Radosevic N et al. Coping with changes in Defined Daily 
Dose in longitudinal drug consumption databases. Pharm World Sci 2010; 32:125-9  
84. McDowall, D, McCleary, R, Meidinger, EE, Hay, RA (1980) Interrupted time series analysis. In: 
Sage University Papers Series on Quantitative Applications in the Social Sciences, 07±021. 
Thousand Oakes, CA: Sage Publications Inc. 
 15 
 
85. Ross-Degnan D, Soumerai SB, Fortess EE, Gurwitz JH (1993) Examining product risk in context. 
Market withdrawal of zomepirac as a case study. Journal of the American Medical Association, 
270, 1937±1942. 
86. Durbin J, Watson GS. Testing for serial correlation in least square regression. Biometrika 1951; 
37, 409±428. 
87. Brennan P, Croft P. Interpreting the results of observational research: chance is not such a fine 
thing. BMJ 1994; 309: 727±730. 
88. Vogler S, Zimmermann N, Leopold C, de Joncheere K. Pharmaceutical policies in European 
countries in response to the global financial crisis. Southern Med Review. 2011;4(2):22-32. 
89. Maher AR, Maglione M, Bagley S, Suttorp M et al. Efficacy and comparative effectiveness of 
atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-
analysis. JAMA. 2011 Sep 28;306:1359-69 
90. Scottish Quality Prescribing Initiative 2012. Available via URL: 
www.sehd.scot.nhs.uk/pca/PCA2012(M)08.pdf [Accessed 25 May 2012] 
91. Chue P, Chue J. The cost-effectiveness of risperidone long-acting injection in the treatment of 
schizophrenia. Exp Re. Pharmacoecon Outcome Res 2012; 12:259-69  
92. Lambert T, Emmerson B, Hustig H. Long acting risperidone in Australian patients with chronic 
schizophrenia: 24-month data from the e-STAR database. BMC Psychiatry 2012, 12:25 
93. Willis M, Svensson M, Löthgren M, Eriksson B et al. The impact on schizophrenia-related hospital 
utilization and costs of switching to long-acting risperidone injections in Sweden. Eur J Health 
Econ. 2010;11(6):585-94.  
94. Rosenheck RA, Barnett PG, Hicks P, Krystal JH, Lew R et al. Cost and cost-effectiveness in a 
randomized trial of long-acting risperidone for schizophrenia. J Clin Psychiatry. 2012;73(5):696-
702. 
95. Covell NH, McEvoy JP, Schooler NR et al. Effectiveness of switching from long-acting injectable 
fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an 
open-label, randomized controlled trial. J Clin Psychiatry. 2012;73(5):669-75 
96. Taylor D, Fischetti C, Sparshatt A, Thomas A, Bishara D, Cornelius V. Risperidone long-acting 
injection: a 6-year mirror-image study of healthcare resource use. Acta Psychiatr Scand. 
2009;120(2):97-101 
97. Pechlivanoglou P, Vehof J, van Agthoven M, de Jong-van den Berg LT, Postma MJ. Diffusion of a 
new drug: a comparative analysis of adoption, treatment complexity, and persistence of 
risperidone long-acting injectable therapy in the Netherlands. Clin Ther.;32(1):108-18 
98. Gaebel W, Schreiner A, Bergmans P et al. Relapse prevention in schizophrenia and 
schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-
term, open-label, randomized clinical trial. Neuropsychopharmacology. 2010; 35(12):2367-77 
